What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Pan-ERR agonist · exercise mimetic compound
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing SLU-PP-332 inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
SLU-PP-332 is a small-molecule pan-agonist of the three Estrogen-Related Receptor isoforms (ERRα, ERRβ, ERRγ), developed at Saint Louis University as a research tool for studying ERR-mediated transcriptional regulation of mitochondrial biogenesis and oxidative metabolism. ERRs are orphan nuclear receptors (no endogenous ligand identified despite their estrogen-receptor sequence homology) that act as master transcriptional regulators of the OXPHOS and TCA-cycle gene-expression programs, particularly in skeletal muscle, heart, and brown adipose tissue. SLU-PP-332's activity profile produces gene-expression changes similar to endurance-exercise training, putting it in the same broad mechanistic category as AICAR but acting through a distinct molecular target. PeptideXpo supplies SLU-PP-332 at ≥99.0% HPLC purity. As a small molecule, the analytical workflow uses RP-HPLC plus mass spec for identity. Two fill sizes (5 mg and 10 mg) cover the typical research scales for nuclear-receptor pharmacology studies, which generally require lower absolute amounts than AMPK-activation studies because nuclear receptor signaling cascades amplify the input ligand concentration.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation in jurisdictions where local regulations permit. Not a finished dosage form and not labeled for direct human administration as shipped. The GLP-1 class is on active regulatory watchlists in several major markets, buyers are responsible for verifying current scheduling and compounding eligibility for the destination at the time of dispense.
Frequently asked questions
The Estrogen-Related Receptors (ERRα, ERRβ, ERRγ) are nuclear receptors with sequence homology to the classical estrogen receptors (ERα, ERβ) but with a completely different ligand and gene-target profile. Despite the name, ERRs are not activated by estradiol or other estrogens, they are 'orphan' nuclear receptors with no identified endogenous ligand. ERRs constitutively activate transcription of genes involved in mitochondrial biogenesis, OXPHOS subunit expression, fatty-acid oxidation, and TCA-cycle enzymes. They function as 'master switches' for the oxidative-metabolism gene expression program, particularly in tissues with high energy demands (muscle, heart, brown adipose). SLU-PP-332 is a synthetic small-molecule agonist of all three ERR isoforms, providing the exogenous activator that nature didn't provide.
Both compounds produce gene-expression changes similar to endurance-exercise training but through completely different mechanisms. AICAR works at the cytoplasmic AMPK kinase level, mimicking the AMP-rise signal that energy depletion would produce, and then triggering AMPK-downstream effects on transcription. SLU-PP-332 works directly at the nuclear-receptor transcriptional level, activating the ERR-controlled oxidative-metabolism gene expression program without going through cytoplasmic energy-sensing. The two compounds therefore engage parallel rather than identical pathways, and they can be combined in research workflows studying the contribution of each layer of exercise-mimetic biology.
Published mechanistic studies of SLU-PP-332 typically use cellular working concentrations in the 0.1-10 μM range, substantially lower than AICAR's mM-range working concentrations because nuclear receptor signaling cascades amplify input ligand concentration through transcriptional gain. EC50 values for SLU-PP-332 at ERRα, ERRβ, and ERRγ are in the 100-500 nM range in published cellular reporter assays. For dose-response work, the typical experimental design uses a 7-point dilution from 10 nM to 10 μM. Working stocks should be prepared in DMSO (the molecule's polar functional groups limit aqueous solubility); final assay DMSO concentrations should remain below 0.1% to avoid solvent effects on the cellular transcriptional readouts.
SLU-PP-332 is a pan-ERR agonist, it activates all three ERR isoforms with relatively comparable potency rather than selectively engaging one of the three. This is the principal pharmacological feature distinguishing it from isoform-selective ERR ligands developed by other groups. For research workflows studying ERR biology in tissues where multiple isoforms are co-expressed (skeletal muscle expresses all three; brown adipose primarily expresses ERRα), the pan-agonist profile is useful because it activates the full ERR transcriptional program without isoform bias. For research distinguishing the contributions of individual isoforms, isoform-selective ligands (e.g., DY131 for ERRβ/γ) are more appropriate research tools.
Related peptides
